RESUMEN
INTRODUCTION: We aimed to investigate the secondary fracture rates and risk factors in patients with proximal femoral fractures using fracture liaison service (FLS) during the coronavirus disease (COVID)-19 pandemic. MATERIALS AND METHODS: In this multi-center prospective cohort study, patients with proximal femoral fractures who were treated surgically at three hospitals from April 2020 to March 2021 were included. Follow-up examinations at 6 and 12 months postoperatively were conducted to investigate the clinical data and ascertain whether osteoporosis treatment could be continued. RESULTS: A total of 316 patients with proximal femoral fractures were registered. During the follow-up period, 17 patients died and 67 patients could not visit the hospitals owing to the COVID-19 pandemic. In total, 172 patients who could be followed-up 12 months postoperatively were examined using dual-energy X-ray absorptiometry during hospitalization; underwent postoperative osteoporosis treatment, mainly with bisphosphonates (89.5%); and were administered medications continuously. Secondary fractures occurred within 1 year in 14 patients (8.1%). Multivariate analysis showed that patients who used sleeping pills and had a lower functional independence measure had an increased risk for developing secondary fractures. CONCLUSION: During the COVID-19 pandemic, secondary fractures can be prevented if the patients can be followed and osteoporosis treatment can be continued. Conversely, despite adequate osteoporosis drug examination and treatment, a certain number of secondary fractures still occurred. The finding that postoperative osteoporosis therapy using routine medications and rehabilitation is associated with secondary fractures may support the importance of establishing clinical standards consisting of a multidisciplinary collaboration for FLS.
Asunto(s)
Conservadores de la Densidad Ósea , COVID-19 , Osteoporosis , Fracturas Osteoporóticas , Fracturas Femorales Proximales , Humanos , Fracturas Osteoporóticas/epidemiología , Fracturas Osteoporóticas/prevención & control , Conservadores de la Densidad Ósea/uso terapéutico , Estudios Prospectivos , Pandemias , Osteoporosis/complicaciones , Osteoporosis/tratamiento farmacológico , Osteoporosis/epidemiología , Factores de RiesgoRESUMEN
The title compound, C10H10O4, was synthesized from tetra-methyl-1,4-benzo-quinone. In the crystal, the almost planar mol-ecule (r.m.s. deviation = 0.024â Å) forms intra-molecular hydrogen bonds between the aldehyde and hy-droxy groups and exhibits C 2v symmetry. This achiral mol-ecule crystallizes in the chiral space group P21 with inter-molecular O-Hâ¯O and C-Hâ¯O hydrogen bonding and C-Hâ¯π and C=Oâ¯π inter-actions stabilizing the crystal packing.